COVID-19 in people with HIV in the Netherlands
- PMID: 37199566
- PMCID: PMC10399951
- DOI: 10.1097/QAD.0000000000003597
COVID-19 in people with HIV in the Netherlands
Abstract
Objectives: We investigated occurrence of and risk factors for severe COVID-19 outcomes in people with HIV (PWH) in the Netherlands.
Design: An ongoing prospective nationwide HIV cohort study.
Methods: COVID-19 diagnoses and outcomes with other relevant medical information were prospectively collected from electronic medical records in all HIV treatment centers in the Netherlands, from the start of the COVID-19 epidemic until December 31, 2021. Risk factors for COVID-19 related hospitalization and death were investigated using multivariable logistic regression, including demographics, HIV-related factors, and comorbidities.
Results: The cohort comprises 21 289 adult PWH, median age 51.2 years, 82% male, 70% were of Western origin, 12.0% were of sub-Saharan African and 12.6% Latin American/Caribbean origin, 96.8% had HIV-RNA less than 200 copies/ml, median CD4 + cell count 690 (IQR 510-908) cells/μl. Primary SARS-CoV-2 infections were registered in 2301 individuals, of whom 157 (6.8%) required hospitalization and 27 (1.2%) ICU admission. Mortality rates were 13 and 0.4% among hospitalized and nonhospitalized individuals, respectively. Independent risk factors for severe outcomes (COVID-19-related hospitalization and death) were higher age, having multiple comorbidities, a CD4 + cell count less than 200 cells/μl, uncontrolled HIV replication, and prior AIDS diagnosis. Migrants from sub-Saharan Africa, Latin America, and the Caribbean were at an increased risk of severe outcomes independently of other risk factors.
Conclusion: In our national cohort of PWH, risk of severe COVID-19 outcomes was increased in individuals with uncontrolled HIV replication, low CD4 + cell count, and prior AIDS diagnosis, independently of general risk factors such as higher age, comorbidity burden and migrants originating from non-Western countries.
Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc.
Conflict of interest statement
F.W. has received fees from ViiV for participation on advisory boards; P.R. through his institution has received independent scientific grant support from Gilead Sciences, Janssen Pharmaceuticals Inc, Merck & Co and ViiV Healthcare, and has served on scientific advisory boards for Gilead Sciences, ViiV Healthcare, and Merck & Co honoraria for which were all paid to his institution; B.R. has received research grants from Gilead, research grants from Merck Sharp and Dohme and honoraria from Jansen-Cilag, BMS, Pfizer, and ViiV; C.R. has received fees for advisory boards and unrestricted research grants from Gilead Sciences and ViiV; A.R. has disclosed no conflicts of interest; K.B. has disclosed no conflicts of interest; MvdV through his institution has received fees for advisory boards and unrestricted research grants from Gilead Sciences, Merck, and ViiV.
Figures
Comment in
-
More evidence for inequitable COVID-19 outcomes in people with HIV.AIDS. 2023 Sep 1;37(11):1763-1764. doi: 10.1097/QAD.0000000000003643. AIDS. 2023. PMID: 37534727 Free PMC article. No abstract available.
References
-
- Coronadashboard | COVID-19 | Rijksoverheid.nl. https://coronadashboard.rijksoverheid.nl/ [Accessed 15 July 2022].
-
- COVID-19 dataset. https://data.rivm.nl/covid-19/ [Accessed 15 July 2022].
-
- Stichting Werkgroep Antibioticabeleid. Leidraad Medicamenteuze behandeling voor patiënten met COVID-19 (infecties met SARS-CoV-2). 2022. [Dutch Working Party on Antibiotic Policy (Dutch acronym is SWAB). Guideline for the medical treatment for patients with COVID-19 (infection with SARS-CoV-2)]. Available at https://richtlijnendatabase.nl/richtlijn/covid-19/behandeling/medicament....
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous
